← board
NRC
distress 2/10 · well-funded / low risk$21.47-1%today-6% from 52w high
Revenue
$35M
Liquidity
$3M
Runway
—
Shares 1y
-2%
Price & events
-0.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-2.1%
1W
+8.0%
1M
+25.4%
3M
+3.6%
6M
+50.8%
1Y
-7.0%
2Y
-53.2%
5Y
-42.7%
All
Overview
- Market Cap
- $483.86M
- Enterprise Value
- $555.33M
- Volume
- 878
- 52 Week Range
- $11.42 – $22.77
- Total Shares
- 22.54M
- Float Shares
- 12.23M
- Short %
- 16.60%
- % Held by Insiders
- 48.87%
- % Held by Institutions
- 49.62%
- RVOL
- 0.01x
- Beta
- 0.38
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-07-28Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $23 (+7% upside) · 1 analysts
- 2026-06-22CitizensMarket Outperform
Competitors
- none identified
Recent news
- 2026-07-22NRC Health (NRC) 16th Annual East Coast IDEAS Conference Summary - Quartr
- 2026-07-22NRC Health (NRC) Proxy filing Summary - Quartr
- 2026-07-22NRC Health (NRC) Q1 2026 earnings summary - Quartr
- 2026-07-22NRC Health (NRC) Investor presentation Summary - Quartr
- 2026-07-22NRC Health (NRC) Status update Summary - Quartr
- 2026-07-21NRC Q2'26 Earnings: revenue estimate is 34.90M USD - TradingView
- 2026-06-26FDA Proposes Rule That Would Help Hold Foreign Tobacco Product Manufacturers Accountable, Protect Public Health
- 2026-06-25NRC Health (NRC) director awarded $150,000 in restricted stock units - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.